Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Glaucoma, Open Angle or Ocular Hypertension
Interventions: brinzolamide 1% ophthalmic suspension, Azopt 1%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome
Interventions: Travatan, Azopt, Alphagan P; Drug
Lead sponsor: Hermann Eye Center; Other
Eligibility: 35 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 21
States / cities: Los Angeles, California • Hamden, Connecticut • Gainesville, Florida + 14 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution, DE-117 Middle/High Dose ophthalmic solution, DE-117 High Dose ophthalmic solution, latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Chandler, Arizona • Artesia, California • Glendale, California + 11 more

Conditions: Glaucoma, Open-Angle
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Mankind Pharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Bakersfield, California • Mission Hills, California • Newport Beach, California + 5 more

Conditions: Primary Open Angle Glaucoma
Interventions: motivational interviewing, three phone calls to remind patients to take their eye drops; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Aurora, Colorado • Portland, Oregon

Conditions: Glaucoma, Healthy
Interventions: Variation in eye pressure response to timolol and latanoprost treatment; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years and older
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Omaha, Nebraska

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Travoprost, Placebo Vehicle; Drug · Other
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 10
States / cities: Artesia, California • Colorado Springs, Colorado • Lakeland, Florida + 7 more

Conditions: Glaucoma
Interventions: Lutein, zeaxanthin and mesozeaxanthin, Placebo; Drug · Other
Lead sponsor: Felipe Medeiros, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: JV-GL1, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: JeniVision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma
Interventions: Tono-Vera tonometer, Goldman Applanation Tonometry; Device
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Glaucoma, Ocular Hypertension (OH)
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Artesia, California • Los Angeles, California • San Diego, California + 3 more

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 30 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Glaucoma, Ocular Hypertension
Interventions: brimonidine 0.1%, Apraclonidine 0.5%; Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Glaucoma, OHT - Ocular Hypertension
Interventions: Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution; Combination Product · Drug
Lead sponsor: PolyActiva Pty Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Primary Open Angle Glaucoma, Hypertension Ocular
Interventions: Pulsed Electromagnetic Field Therapy, Seawater eyedrops; Device · Drug
Lead sponsor: American Society Of Thermalism And Climatology Inc; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Glaucoma, Open-Angle
Interventions: Not listed
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 24
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Santa Rosa, California + 20 more

Conditions: Ocular Hypertension, Suspect Glaucoma
Interventions: Rocklatan (Netarsudil 0.02%/ latanoprost 0.005), Latanoprost (0.005%); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Columbia, Maryland • Silver Spring, Maryland

Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension
Interventions: Travoprost 0.004%, Travoprost Vehicle, Travoprost (Groups A, B and C); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Open-Angle
Interventions: Standard Automatic Perimetry Humphrey Field Analyzer, visuALL Field Analyzer; Diagnostic Test
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Open Angle Glaucoma (POAG)
Interventions: CyPass Micro-Stent, Cataract Surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Glendale, Arizona • Fayetteville, Arkansas • La Jolla, California + 19 more

Conditions: Glaucoma
Interventions: Baerveldt 350 implant, Ahmed ClearPath 350 implant; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma, Open-Angle
Interventions: Video education on proper eye drop instillation technique, Placebo video education on healthy eating tips; Other
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

RESEARCH PROTOCOL: Glaucoma Treatment Adherence and Persistence

Glaucoma Biomarkers

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

Macular Pigment and Visual Performance in Glaucoma Patients

Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Comparison of Intraocular Pressure Measurement With the Novel TonoVera Device With Other Commonly Used Devices

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

The Study of Ocular Hemodynamics With Glaucoma Progression

Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension

Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion.

iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

Travoprost Five Day Posology Study

visuALL Field Analyzer (vFA) Compared to Standard Humphrey Automated Perimetry

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

The Baerveldt Versus ClearPath Comparison Study

Glaucoma Eye Drop Instillation: Impact of Education